Biennial mammography optimal screening interval for average risk women
the ONA take:
A comprehensive analysis of digital mammography tests has indicated that biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
This screening frequency should offer a good balance between prudent detection and the risk of false-positive results.
The study findings indicated that biennial screening maintains an average of 81.2% of annual screening benefits with fewer false-positives; whereas annual screening, although it could avert 3 more cancer deaths, would yield approximately 1988 additional false-positive test results.
This study was a collaboration between six modeling research groups that belong to CISNET, the NCI-sponsored Cancer Intervention and Surveillance Modeling Network, coupled with investigators based at the Breast Cancer Surveillance Consortium (BCSC).
The paper's lead author was Jeanne S. Mandelblatt, MD, MPH, of Georgetown Lombardi Comprehensive Cancer Center (CISNET).
The modeling incorporated national data on breast cancer risk, treatment effects, and incidence of breast cancer; and reviewed one- and two-year screening intervals on individuals with varying starting ages. The research also considered digital screening and breast density factors.
Other modeling findings revealed that biennial screening during the age span of 50-74 would achieve a roughly 25% mortality reduction. Starting the biennial screening at age 40 averts an average of one additional cancer death but also generates an average of 576 additional false-positive tests.
The paper's lead author cautioned that these model findings should still not override a screening frequency determination based on individual factors, based on acceptance of false-positive results, over treatment, etc. She stated that screening frequency must be balanced against the risk of chemotherapy and/or radiation treatment that may not needed.
Biennial (once every two years) screening is preferable for women of age 50 through 74 that have an average risk of developing breast cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|